Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:FOLD NASDAQ:LGND NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.87+2.7%$27.87$25.17▼$36.45$4.60B0.531.80 million shs1.42 million shsFOLDAmicus Therapeutics$8.22-1.2%$7.31$5.51▼$12.65$2.53B0.553.96 million shs3.54 million shsLGNDLigand Pharmaceuticals$169.56+1.7%$153.98$93.58▼$172.45$3.32B0.96156,621 shs119,627 shsMNKDMannKind$5.51+3.3%$4.48$3.38▼$7.63$1.69B1.022.82 million shs4.21 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-2.45%-4.97%-6.38%-5.83%+2.65%FOLDAmicus Therapeutics-0.36%-1.89%+10.64%+40.30%-23.53%LGNDLigand Pharmaceuticals-1.30%-1.81%+4.38%+46.09%+68.82%MNKDMannKind0.00%-4.99%+30.96%+41.76%-16.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.87+2.7%$27.87$25.17▼$36.45$4.60B0.531.80 million shs1.42 million shsFOLDAmicus Therapeutics$8.22-1.2%$7.31$5.51▼$12.65$2.53B0.553.96 million shs3.54 million shsLGNDLigand Pharmaceuticals$169.56+1.7%$153.98$93.58▼$172.45$3.32B0.96156,621 shs119,627 shsMNKDMannKind$5.51+3.3%$4.48$3.38▼$7.63$1.69B1.022.82 million shs4.21 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-2.45%-4.97%-6.38%-5.83%+2.65%FOLDAmicus Therapeutics-0.36%-1.89%+10.64%+40.30%-23.53%LGNDLigand Pharmaceuticals-1.30%-1.81%+4.38%+46.09%+68.82%MNKDMannKind0.00%-4.99%+30.96%+41.76%-16.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 3.00Buy$42.0050.68% UpsideFOLDAmicus Therapeutics 2.89Moderate Buy$15.7891.87% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.504.09% UpsideMNKDMannKind 3.17Buy$11.17102.85% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, ALKS, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/26/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$42.00 ➝ $44.009/18/2025FOLDAmicus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$14.009/18/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B2.95$2.66 per share10.49$9.05 per share3.08FOLDAmicus Therapeutics$528.29M4.80N/AN/A$0.65 per share12.65LGNDLigand Pharmaceuticals$167.13M19.88$1.61 per share105.15$43.95 per share3.86MNKDMannKind$285.50M5.92$0.14 per share38.41($0.29) per share-18.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0813.4020.351.5623.15%24.86%17.14%10/23/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A19.12N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A45.70N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)MNKDMannKind$27.59M$0.1150.0523.93N/A10.87%-32.60%7.81%11/6/2025 (Estimated)Latest MNKD, ALKS, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/23/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85FOLDAmicus Therapeutics1.923.212.29LGNDLigand PharmaceuticalsN/A5.455.21MNKDMannKindN/A2.502.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableMNKDMannKind400306.83 million298.54 millionOptionableMNKD, ALKS, LGND, and FOLD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Shares Down 5% - Time to Sell?September 23 at 5:21 PM | marketbeat.comVoya Investment Management LLC Sells 58,689 Shares of MannKind Corporation $MNKDSeptember 22, 2025 | marketbeat.comMannKind's (MNKD) Buy Rating Reaffirmed at HC WainwrightSeptember 20, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Receives "Buy" Rating from HC WainwrightSeptember 19, 2025 | marketbeat.comStuart Tross Sells 47,000 Shares of MannKind (NASDAQ:MNKD) StockSeptember 18, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Short Interest Down 23.9% in AugustSeptember 18, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,000 SharesSeptember 18, 2025 | insidertrades.comMannKind (NASDAQ:MNKD) Stock Price Down 4.2% - Time to Sell?September 16, 2025 | marketbeat.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHSeptember 16, 2025 | businesswire.comGoldman Sachs Group Inc. Sells 780,939 Shares of MannKind Corporation $MNKDSeptember 16, 2025 | marketbeat.comMillennium Management LLC Acquires 2,375,198 Shares of MannKind Corporation $MNKDSeptember 13, 2025 | marketbeat.comMannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comMannKind (MNKD): A Fresh Look at Valuation Following New United Therapeutics Deal ExpansionSeptember 10, 2025 | finance.yahoo.comJacobs Levy Equity Management Inc. Boosts Stock Position in MannKind Corporation $MNKDSeptember 10, 2025 | marketbeat.comMannKind Corporation $MNKD Shares Sold by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comMannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comMannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comMannKind Corporation $MNKD Stake Decreased by Nitorum Capital L.P.September 7, 2025 | marketbeat.comPDT Partners LLC Makes New Investment in MannKind Corporation $MNKDSeptember 7, 2025 | marketbeat.comFY2028 EPS Estimates for MannKind Boosted by HC WainwrightSeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNKD, ALKS, LGND, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$27.87 +0.74 (+2.74%) Closing price 03:59 PM EasternExtended Trading$27.89 +0.02 (+0.06%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Amicus Therapeutics NASDAQ:FOLD$8.22 -0.10 (-1.17%) Closing price 03:59 PM EasternExtended Trading$8.24 +0.01 (+0.15%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$169.56 +2.80 (+1.68%) Closing price 03:59 PM EasternExtended Trading$169.70 +0.13 (+0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$5.50 +0.18 (+3.28%) Closing price 03:59 PM EasternExtended Trading$5.54 +0.03 (+0.54%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Why Wall Street Is Betting Billions on Oklo's Nuclear Vision CrowdStrike’s Investor Day Sparks Bullish Momentum Cintas Stock Sends a Clear Buy Signal as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
